Pfizer's 3rd attempt to reimburse ATTR-CM drug ‘Vyndamax'
By Eo, Yun-Ho | translator Alice Kang
22.02.27 17:26:48
가나다라
0
Fails RSA attempt after failing to be listed as an essential medicine… plans to apply for reimbursement again after data supplementation
The only available treatment option… demonstrated its reduction in risk of death and cardiovascular-related hospitalization
The third attempt at reimbursement for Vyndamax, a new drug for transthyretin amyloid cardiomyopathy, has been made by its company.
According to industry sources, Pfizer Korea had again applied for the insurance reimbursement of its new drug that is indicated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This is the company’s third attempt.
Earlier last year, Pfizer failed to first designate Vyndamax as an essential medicine. In the first half of the same year, the company made the second attempt at reimbursement using the Risk-sharing Agreement but failed again.
With perseverance, the company made its third attempt in 2022.
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)